• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C

    2016-04-28 01:43:37LiLiChunYanGouJingYingLiRehmatullahAchakzaiandXiuHuiLiBeijingChina

    Li Li,Chun-Yan Gou,Jing-Ying Li,Rehmatullah Achakzai and Xiu-Hui LiBeijing,China

    ?

    Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C

    Li Li,Chun-Yan Gou,Jing-Ying Li,Rehmatullah Achakzai and Xiu-Hui Li
    Beijing,China

    BACKGROUND:The Barcelona Clinic Liver Cancer(BCLC)staging system for hepatocellular carcinoma(HCC)recommends transarterial chemoembolization(TACE)as the first line therapy for stage B patients and sorafenib treatment for stage C patients.However,stage C patients exhibit variations in terms of tumor burden,liver function,and extrahepatic metastasis,which could potentially affect disease outcome.Here,we assessed whether the Cancer of the Liver Italian Program(CLIP)scores can help identify stage C patients likely to benefit from TACE.

    METHODS:Out of 295 BCLC stage C HCC patients enrolled between January 2009 and December 2011,those with platelet counts >30×109cells/L,total bilirubin <51 μmoL/L,and an unobstructed main portal vein were scheduled for TACE(n=195).The remaining patients received best supportive care(BSC,n=100).All the patients were followed up for symptoms,performance status,and Child-Pugh classification scores every 4 weeks until death or December 2013.The prognosis of each group was evaluated by using the log-rank test and Cox-Mantel test.

    RESULTS:The median overall survival(OS)was 6 months [95% confidence interval(CI):4.64-7.36].The OS was 9 months for the TACE group and 4 months for the BSC group.The TACE group had a longer OS than the BSC subgroup for CLIP scores 0-2 [13 months(95% CI:8.55-17.45)vs 4 months(95% CI:0.00-10.96),P=0.001].No significant differences were found between the TACE and BSC groups for CLIP scores 3-5.The CLIP score and treatment methods were found to be independent prognostic factors.

    CONCLUSIONS:BCLC stage C HCC patients exhibit definite disease heterogeneity and can be reclassified by using the CLIP scoring system.Moreover,patients with CLIP scores 0-2 are likely to benefit from TACE.However,additional studies with long-term follow-up will be required to validate these findings.

    (Hepatobiliary Pancreat Dis Int 2016;15:152-157)

    KEY WORDS:hepatocellular carcinoma;

    BCLC staging system;

    CLIP scoring system;

    transarterial chemoembolization

    Author Affiliations:Department of Combined TCM and Western Medicine,Beijing You’an Hospital(Li L,Gou CY,Li JY and Li XH)and International School(Achakzai R),Capital Medical University,Beijing 100069,China Corresponding Author:Xiu-Hui Li,MD,Department of Combined TCM and Western Medicine,Beijing You’an Hospital,Capital Medical University,No.8,Xi Tou Tiao,You’anmen Wai,Fengtai District,Beijing 100069,China(Fax:+86-10-63296491;Email:lixiuhui@sohu.com)

    ? 2016,Hepatobiliary Pancreat Dis Int.All rights reserved.

    Published online February 24,2016.

    Introduction

    H epatocellular carcinoma(HCC)is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide.[1,2]According to the practice guidelines of the American Association for the Study of Liver Diseases(AASLD)for HCC,the Barcelona Clinic Liver Cancer(BCLC)system is the only staging system that can match patient groups to therapies across the continuum of disease heterogeneity seen with HCC.[3,4]Based on the BCLC staging system,transarterial chemoembolization(TACE)is recommended as the first line non-curative therapy for patients with large or multifocal HCC without vascular invasion or extrahepatic metastasis(BCLC stage B),whereas sorafenib is recommended as first line therapy for advanced(BCLC stage C)HCC patients requiring liver function protection who are less likely to benefit from curative therapy or TACE.[5-7]

    However,sorafenib is not always available for some HCC patients due to financial limitations,especially in developing countries.In Asian countries,TACE has been widely used for patients with unresectable HCC,including those with portal vein thrombosis and extrahepatic metastasis,because of its good survival benefit and over-all safety for selected patients.[8-13]Tumor burden,liver function,portal vein invasion,and extrahepatic metastasis vary among BCLC stage C patients.This heterogeneity suggests different prognostic outcomes in these patients and the possibility that there are different strata of BCLC stage C patients with variable prognosis and requiring different optimal therapies.

    In this study,we analyzed the overall survival(OS)and prognostic factors of BCLC stage C patients with HCC and found that the Cancer of the Liver Italian Program(CLIP)scoring system could more accurately stratify the patients with different outcomes.[15]

    Methods

    Patients

    We enrolled 295 HCC patients who were initially classified into BCLC stage C between January 2009 and December 2011.The diagnosis of HCC was made according to the AASLD guidelines.[5]

    The inclusion criteria were:(1)Eastern Cooperative Oncology Group(ECOG)performance status of 1-2;(2)liver function reserve of class A-B on Child-Pugh classification;(3)Okuda stage 1-2;(4)portal vein tumor thrombosis and/or extrahepatic metastasis;and(5)patients treated with TACE or supportive treatment.Patients with a secondary malignancy or with severe organ function failure were excluded.OS was calculated from the date of enrollment till the date of death or December 31,2013.Gender,age,etiology,Child-Pugh class,CLIP score,tumor size,type,and extent,portal vein tumor thrombosis,extrahepatic metastasis,platelet count,serum aspartate aminotransferase(AST),and serum alpha-fetoprotein(AFP)level were included as baseline variables.

    The study protocol was approved by the Ethics Committee of Beijing You’an Hospital,Capital Medical University and adhered to the Declaration of Helsinki.Because of the retrospective nature of the study,written informed consent was waived off by the approval of the institutional review board.

    Treatment

    On the basis of our experience,patients with platelet count >30×109cells/L,total bilirubin <51 μmoL/L,and a main portal vein that was not completely obstructed by tumor thrombosis were scheduled for TACE.The patients were reevaluated after 3 to 4 weeks;in the interim,they were given symptomatic treatment as required.TACE would be repeated in the event of a residual tumor or if tumor recurrence was confirmed by computed tomography(CT)or magnetic resonance imaging(MRI)during follow-up.Patients who refused to undergo TACE or those who were not considered as suitable candidates for TACE were given symptomatic treatment or best supportive care(BSC).

    TACE

    Overall,195 patients underwent TACE.First,angiography was performed to identify the targeted feeding arteries of the tumor.The catheter was advanced to the hepatic artery and then to the lobar and segmental branches to facilitate maximum selectivity.A combination of chemotherapeutic agents and iodized oil was injected into the arteries,and a gelatin sponge was used to embolize the feeding artery.Doxorubicin(50 mg/m2)or 5-fluorouracil(500 mg/m2)was used as chemotherapeutic agent.The quantities of the iodized oil and sizes of the gelatin sponges used to embolize the tumors were decided by two senior interventional physicians at our center based on the tumor sizes.

    Follow-up

    The patients were followed up for symptoms,ECOG performance status,and Child-Pugh classification with a physical examination every 4 weeks.They underwent enhanced MRI and CT scanning every 4 to 8 weeks until death or the end point of follow-up,December 31,2013.

    Statistical analysis

    All data were analyzed with the SPSS statistical software(IBM SPSS Statistics 21).Disease-specific survival was analyzed using the Kaplan-Meier method.The logrank test was used to analyze differences in survival.Multivariate analysis was performed using the Cox proportional hazards model with forward stepwise selection.A P value of <0.05 was considered statistically significant.

    Results

    Baseline characteristics of TACE and no-TACE patient Of the 295 patients,195(66.1%)received TACE(TACE group)and 100(33.9%)received symptomatic treatment or BSC(BSC group).TACE was repeated in 91 of the 195 patients;the median session of TACE procedures per patient was 2(range 1-8).Baseline characteristics of the patients are shown in Table 1.Gender,age,etiology,tumor size,extent,metastasis,platelet count,and the levels of AST and AFP were not significantly different between the two groups(Table 1).The baseline Child-Pugh class,CLIP score,portosytemic shunt,and portal vein invasion status were significantly different between the two groups,with patients in the BSC group having a moreadvanced disease status compared with the TACE group.

    Table 1.Baseline variables of the patients with BCLC stage C HCC(n,%)

    Analysis of prognosis

    The median OS was 6 months [95% confidence interval(CI):4.64-7.36] for all patients(Fig.1).The 1- and 2-year OS rates were 32.9% and 12.8%,respectively(P=0.001).

    In the Cox regression test,univariate analysis showed that the median OS was significantly longer in the TACE group than in the BSC group(9 vs 4 months,respectively;P=0.001;Table 2,Fig.2).Additionally,OS was significantly correlated with CLIP score(OS,12 months and 5 months for score 0-2 and score 3-5,respectively,P=0.001;Table 2,Fig.3),extent of tumor(OS,8 months and 4 months for ≤50% and >50%,respectively,P=0.001),portal vein thrombosis(OS,4 months and 7 months for groups with and without portal vein thrombosis,respectively,P<0.001),Child-Pugh class(OS,9 months and 4 months for class A and B,respectively,P=0.001),and AFP level(OS,8 months and 5 months for <400 ng/mL and ≥400 ng/mL,respectively,P=0.035)(Table 2).

    Fig.1.Kaplan-Meier curve of patients with BCLC stage C HCC.The median OS was 6 months(95% confidence interval:4.64-7.36,n=295).

    Fig.2.Kaplan-Meier curves for different treatment subgroups.The overall survival in the TACE group(median OS:9 months,n=195)was significantly longer than in the BSC group(median OS:4 months,n=100).

    Multivariate analysis,excluding the influence of con-founding factors,identified both the treatment method and CLIP score as independent prognostic factors for longer OS(P=0.001 in both cases;Table 3).

    Of note,subgroup analyses showed that patients with CLIP scores of 0-2 obtained more benefit from TACE than from BSC(P=0.001);the median OS was 13 months(95% CI:8.55-17.45)and 4 months(95% CI:0.00-10.96)in the TACE and BSC groups,respectively(Table 4,Fig.4A).In patients with CLIP scores of 3-5,however,there was no significant difference between the TACE and BSC groups;the median OS was 5 months and 4 months respectively for the two groups(Table 4,Fig.4B).

    Table 2.Univariate analysis for patients survival with BCLC stage C HCC

    Table 3.Multivariate analysis for patients survival with BCLC stage C HCC

    Table 4.Patients survival in the subgroups

    Fig.3.Kaplan-Meier curves for patients of different CLIP score subgroups.The overall survival in the CLIP 0-2 group(median OS:12 months,n=106)was significantly longer than that in the CLIP 3-5 group(median OS:5 months,n=189).

    Fig.4.Kaplan-Meier curves for different treatment subgroups categorized on the basis of CLIP scores.A:Kaplan-Meier curves for different treatment subgroups in patients with CLIP scores 0-2.These patients derived more benefit from TACE(median OS:13 months,n=80)than from BSC case(median OS:4 months,n=26).B:Kaplan-Meier curves for different treatment subgroups in patients with CLIP scores of 3-5.In this patient population,there was no significant difference between TACE(median OS:5 months,n=115)and BSC subgroups(median OS:4 months,n=74).

    Complications

    The incidence of complications was 82.05%(n=160)in the TACE group.The most common treatment-related complications were fever,abdominal pain,or temporary liver function deterioration.Two(1.02%)patients with CLIP scores of 4 and 5 experienced an irreversible deterioration of liver function and died of liver failure approximately 1 and 2 months after TACE,respectively.

    Discussion

    While several staging systems have been developed for HCC,there is no consensus on a universal accepted and optimal staging system that best predicts prognosis in HCC patients.[15-17]The heterogeneity in prevalence and etiology of HCC in different populations results in the inaccuracy of one staging system used in a population different from where it was developed.[17]

    The BCLC staging broadly classifies nonsurgical HCC as stage B(intermediate)or stage C(advanced);BCLC stage C patients have symptomatic tumors(ECOG performance status test,1-2),portal vein tumor invasion,or extrahepatic spread.[4]However,BCLC stage C HCC is known to include a heterogeneous group of patients with heterogeneous prognosis.[18]Patients in our study also showed heterogeneity in several baseline characteristics such as Child-Pugh class,CLIP score,portosystemic shunt,and portal vein invasion status,while other variables such as tumor size,extent,metastasis,and AFP levels were similar between the two study groups.

    While the BCLC staging classification recommends sorafenib as the first line therapy for BCLC stage C patients,[5-7]access to sorafenib is often limited in developing countries and TACE has been recommended and widely used as palliative therapy in China[19]and other Asian countries.[8-13]Studies[11-13]have shown that TACE provides good survival benefit and overall safety for selected patients with advanced HCC.Our study also showed a significantly longer overall survival(median OS,13 months)in patients treated with TACE compared with those treated with BSC(median OS,4 months).These results support TACE as a treatment strategy in advanced-stage HCC.

    Studies[20-23]have identified different prognostic factors for overall survival in BCLC stage C HCC patients.An Austrian study identified Child-Pugh class as the only independent prognostic factor in a group of advanced HCC patients treated by TACE or sorafenib.[20]A Japanese study[21]identified degree of liver damage,TNM stage,and AFP levels,and two Chinese studies[22,23]identified tumor lesion numbers,Child-Pugh class,metastasis,and portal vein invasion,as the independent prognostic factors in advanced HCC treated by TACE.In the present study,we identified that both the treatment method and CLIP score were independent prognostic factors for overall survival in the studied patients.Patients with CLIP 0-2 tumors had a longer OS than those with CLIP 3-5 tumors.Our results suggested that a CLIP score of 0-2 corresponds to better outcome than a higher score,and patients with a low CLIP score may still benefit from active therapy.

    Careful patient selection is known to be crucial for the success of TACE.[20]We found that TACE treatment significantly improved the OS in CLIP 0-2 patients compared with those with higher CLIP scores.Our findings supported that BCLC stage C patients have disease heterogeneity and could be further classified into different strata according to outcomes.Thus,the CLIP scoring system can be used as a useful tool to stratify patients with BCLC stage C HCC.CLIP classification is easy to perform;it considers Child-Pugh class,tumor morphological type,tumor extent,portal vein invasion,and serum AFP levels.CLIP classification thus inherently includes several independent prognostic determinants of HCC and has been shown to possess a higher predictive power than the Okuda classification.[15,24]Our findings also confirm that TACE is an effective therapy for BCLC stage C patients with a CLIP score of 0-2.[16]In this study,we identified the subgroup that could get the maximum benefit from TACE among BCLC stage C HCC patients.Further,TACE related complications observed in this study were comparable to that observed in previous studies suggesting that TACE is generally safe for patients even with advanced HCC.[11,25]

    The main limitations of our study are its retrospective nature and the fact that environmental factors,such as socioeconomic status and alcohol abuse,which affect the prognosis of HCC,were not taken into consideration.Moreover,the results of this study represent the outcomes of a single center in China and may not be universally applicable.

    In conclusion,BCLC stage C patients have disease heterogeneity and can be reclassified using the CLIP scoring system.Patients with CLIP scores 0-2 tend to have better overall survival and are better candidates for TACE.Future studies involving a randomized prospective design and longer follow-up durations are needed to verify whether implementation of different treatment modalities on the basis of CLIP scores result in overall improvement.The CLIP score may also be explored as a tool to identify patients with advanced HCC in clinical trials.

    Contributors:LXH proposed the study.LL and GCY performed the research and wrote the first draft.LJY and AR collected andanalyzed the data.All authors contributed to the design and interpretation of the study and to further drafts.LXH is the guarantor.Funding:This study was supported by grants from You’an Liver disease/AIDS funding(2011),and the National Science &Technology Pillar Program during the 12th Five-year Plan Period(2013BAI13B04).

    Ethical approval:The study protocol was approved by the Ethics Committee of Beijing You’an Hospital,Capital Medical University and adhered to the Declaration of Helsinki.

    Competing interest:No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    References

    1 Parkin DM.Global cancer statistics in the year 2000.Lancet Oncol 2001;2:533-543.

    2 El-Serag HB,Rudolph KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis.Gastroenterology 2007;132:2557-2576.

    3 Bruix J,Sherman M;Practice Guidelines Committee,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma.Hepatology 2005;42:1208-1236.

    4 Llovet JM,Brú C,Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification.Semin Liver Dis 1999;19:329-338.

    5 Bruix J,Sherman M;American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update.Hepatology 2011;53:1020-1022.

    6 Bruix J,Llovet JM.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology 2002;35:519-524.

    7 Heng-jun G,Yao-jun Z,Min-shan C,Mei-xian C,Jun-ting H,Li X,et al.Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.Liver Int 2014;34:612-620.

    8 Luo J,Guo RP,Lai EC,Zhang YJ,Lau WY,Chen MS,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study.Ann Surg Oncol 2011;18:413-420.

    9 Xue TC,Xie XY,Zhang L,Yin X,Zhang BH,Ren ZG.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:a meta-analysis.BMC Gastroenterol 2013;13:60.

    10 Niu ZJ,Ma YL,Kang P,Ou SQ,Meng ZB,Li ZK,et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:using a new classification.Med Oncol 2012;29:2992-2997.

    11 Lee HS,Kim JS,Choi IJ,Chung JW,Park JH,Kim CY.The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction.A prospective controlled study.Cancer 1997;79:2087-2094.

    12 Kim KM,Kim JH,Park IS,Ko GY,Yoon HK,Sung KB,et al.Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.J Gastroenterol Hepatol 2009;24:806-814.

    13 Yoo DJ,Kim KM,Jin YJ,Shim JH,Ko GY,Yoon HK,et al.Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma:does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 2011;26:145-154.

    14 The Cancer of the Liver Italian Progran(CLIP)Investigators.A new prognostic system for hepatocellular carcinoma:a retrospective study of 435 patients:the Cancer of the Liver Italian Program(CLIP)investigators.Hepatology 1998;28:751-755.

    15 Huitzil-Melendez FD,Capanu M,O’Reilly EM,Duffy A,Gansukh B,Saltz LL,et al.Advanced hepatocellular carcinoma:which staging systems best predict prognosis? J Clin Oncol 2010;28:2889-2895.

    16 Farinati F,Rinaldi M,Gianni S,Naccarato R.How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.Cancer 2000;89:2266-2273.

    17 Italian Association for the Study of the Liver(AISF);AISF Expert Panel;AISF Coordinating Committee,Bolondi L,Cillo U,Colombo M,et al.Position paper of the Italian Association for the Study of the Liver(AISF):the multidisciplinary clinical approach to hepatocellular carcinoma.Dig Liver Dis 2013;45:712-723.

    18 Llovet JM,Di Bisceglie AM,Bruix J,Kramer BS,Lencioni R,Zhu AX,et al.Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst 2008;100:698-711.

    19 China MoHotPsRo.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011).J Clinical Hepatol 2011;11:1141-1159.

    20 Pinter M,Hucke F,Graziadei I,Vogel W,Maieron A,K?nigsberg R,et al.Advanced-stage hepatocellular carcinoma:transarterial chemoembolization versus sorafenib.Radiology 2012;263:590-599.

    21 Takayasu K,Arii S,Ikai I,Omata M,Okita K,Ichida T,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.Gastroenterology 2006;131:461-469.

    22 Liu L,Zhang C,Zhao Y,Qi X,Chen H,Bai W,et al.Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis:prognostic factors in a single-center study of 188 patients.Biomed Res Int 2014;2014:194278.

    23 Xiao J,Li G,Lin S,He K,Lai H,Mo X,et al.Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.Int J Clin Exp Pathol 2014;7:1114-1123.

    24 Okuda K,Ohtsuki T,Obata H,Tomimatsu M,Okazaki N,Haregawwa H,et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment.Cancer 1985;56:918-928.

    25 Kim JH,Yoon HK,Kim SY,Kim KM,Ko GY,Gwon DI,et al.Transcatheter arterial chemoembolization vs.chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.Aliment Pharmacol Ther 2009;29:1291-1298.

    Received April 29,2015

    Accepted after revision December 8,2015

    doi:10.1016/S1499-3872(16)60070-X

    丰满人妻熟妇乱又伦精品不卡| 琪琪午夜伦伦电影理论片6080| 搡老熟女国产l中国老女人| 久99久视频精品免费| 午夜视频精品福利| 一本综合久久免费| 免费一级毛片在线播放高清视频| 免费人成视频x8x8入口观看| av有码第一页| 久久久久久免费高清国产稀缺| 曰老女人黄片| 亚洲午夜精品一区,二区,三区| 亚洲一区二区三区不卡视频| 日本一本二区三区精品| 午夜精品久久久久久毛片777| 给我免费播放毛片高清在线观看| 亚洲第一青青草原| 神马国产精品三级电影在线观看 | 国产亚洲精品久久久久5区| 黄色片一级片一级黄色片| 亚洲av成人av| 日本精品一区二区三区蜜桃| 黄片小视频在线播放| 亚洲激情在线av| 又黄又爽又免费观看的视频| 香蕉久久夜色| 日日夜夜操网爽| 国产在线精品亚洲第一网站| 欧洲精品卡2卡3卡4卡5卡区| 免费在线观看亚洲国产| 好男人在线观看高清免费视频 | 脱女人内裤的视频| √禁漫天堂资源中文www| 午夜福利成人在线免费观看| 99久久综合精品五月天人人| 97超级碰碰碰精品色视频在线观看| 亚洲国产中文字幕在线视频| 国产成人啪精品午夜网站| 精品久久久久久成人av| 黄片大片在线免费观看| 视频在线观看一区二区三区| 国产精品九九99| 国产av在哪里看| 身体一侧抽搐| 亚洲 欧美 日韩 在线 免费| 夜夜看夜夜爽夜夜摸| www日本在线高清视频| 欧美另类亚洲清纯唯美| 欧美色欧美亚洲另类二区| 国产熟女午夜一区二区三区| 后天国语完整版免费观看| 大香蕉久久成人网| 免费看十八禁软件| 欧美在线一区亚洲| 欧美黑人巨大hd| 免费观看人在逋| 精品久久久久久久毛片微露脸| or卡值多少钱| 国产精品自产拍在线观看55亚洲| 久久精品影院6| 国产一区二区在线av高清观看| 欧美激情极品国产一区二区三区| 女同久久另类99精品国产91| 亚洲一区二区三区不卡视频| 99久久99久久久精品蜜桃| 黄色毛片三级朝国网站| 一a级毛片在线观看| 亚洲第一av免费看| 久久国产乱子伦精品免费另类| 亚洲国产精品999在线| 国产精品香港三级国产av潘金莲| 国产免费av片在线观看野外av| 午夜a级毛片| 黄片小视频在线播放| 久久精品夜夜夜夜夜久久蜜豆 | 男人舔奶头视频| 精品电影一区二区在线| 国产精品99久久99久久久不卡| 50天的宝宝边吃奶边哭怎么回事| e午夜精品久久久久久久| 国产极品粉嫩免费观看在线| 欧美日韩一级在线毛片| 成年人黄色毛片网站| 欧美成人性av电影在线观看| 欧美成人性av电影在线观看| 日日干狠狠操夜夜爽| 国产精品自产拍在线观看55亚洲| 露出奶头的视频| 在线免费观看的www视频| 亚洲欧美精品综合一区二区三区| 日韩av在线大香蕉| 国产一区二区在线av高清观看| 一a级毛片在线观看| 久久精品91蜜桃| 久久中文字幕一级| 亚洲熟女毛片儿| 侵犯人妻中文字幕一二三四区| 国产视频一区二区在线看| 岛国在线观看网站| 老司机在亚洲福利影院| 亚洲专区国产一区二区| 欧美精品啪啪一区二区三区| 亚洲一区二区三区不卡视频| x7x7x7水蜜桃| 1024香蕉在线观看| 日韩精品中文字幕看吧| 自线自在国产av| 丁香欧美五月| 国产精品香港三级国产av潘金莲| 亚洲成人国产一区在线观看| 变态另类丝袜制服| 国产亚洲欧美在线一区二区| 黑丝袜美女国产一区| 国产精品av久久久久免费| 国产成人精品无人区| 日韩大码丰满熟妇| 欧美成人一区二区免费高清观看 | 久久伊人香网站| 两性夫妻黄色片| 在线观看日韩欧美| 亚洲成人久久爱视频| 首页视频小说图片口味搜索| 首页视频小说图片口味搜索| 午夜福利成人在线免费观看| 男女那种视频在线观看| 可以在线观看毛片的网站| 搞女人的毛片| 一边摸一边做爽爽视频免费| 亚洲中文字幕一区二区三区有码在线看 | 一个人观看的视频www高清免费观看 | 国产av一区在线观看免费| 青草久久国产| 精品国产美女av久久久久小说| 国产又爽黄色视频| 国产男靠女视频免费网站| 日韩欧美国产一区二区入口| 99国产综合亚洲精品| 亚洲av第一区精品v没综合| x7x7x7水蜜桃| 美国免费a级毛片| 国产99白浆流出| 草草在线视频免费看| 一进一出好大好爽视频| 欧美日韩亚洲综合一区二区三区_| 好男人在线观看高清免费视频 | 亚洲精品一卡2卡三卡4卡5卡| 免费在线观看影片大全网站| 国产精品二区激情视频| 男人操女人黄网站| 亚洲国产欧美网| 亚洲中文日韩欧美视频| 999精品在线视频| 免费电影在线观看免费观看| 亚洲成av人片免费观看| 欧美色欧美亚洲另类二区| 亚洲av片天天在线观看| 女人高潮潮喷娇喘18禁视频| 久久中文字幕人妻熟女| 老司机午夜十八禁免费视频| 夜夜夜夜夜久久久久| 亚洲 欧美一区二区三区| 悠悠久久av| 日本精品一区二区三区蜜桃| 国产精品 国内视频| 一边摸一边抽搐一进一小说| 法律面前人人平等表现在哪些方面| 久久久久国产精品人妻aⅴ院| 老熟妇乱子伦视频在线观看| 婷婷亚洲欧美| 久久亚洲精品不卡| 亚洲精华国产精华精| 国产亚洲av嫩草精品影院| 久久午夜综合久久蜜桃| 精品国产超薄肉色丝袜足j| 好男人电影高清在线观看| 国产精品九九99| 欧美zozozo另类| 久99久视频精品免费| 熟妇人妻久久中文字幕3abv| 每晚都被弄得嗷嗷叫到高潮| 人人妻,人人澡人人爽秒播| 国产男靠女视频免费网站| 国产精品精品国产色婷婷| 搡老妇女老女人老熟妇| 亚洲成国产人片在线观看| 久久青草综合色| 国产成人av教育| 国产亚洲精品综合一区在线观看 | 国产精品一区二区免费欧美| 国产伦一二天堂av在线观看| 日韩中文字幕欧美一区二区| 巨乳人妻的诱惑在线观看| or卡值多少钱| 中出人妻视频一区二区| www日本在线高清视频| 午夜福利欧美成人| 桃红色精品国产亚洲av| 精品高清国产在线一区| 中文字幕精品免费在线观看视频| 国产精品香港三级国产av潘金莲| 99久久无色码亚洲精品果冻| 久久久国产成人精品二区| 老司机福利观看| 精品国内亚洲2022精品成人| 最好的美女福利视频网| 久久久久久久精品吃奶| 亚洲精品国产一区二区精华液| 看黄色毛片网站| 亚洲色图 男人天堂 中文字幕| 成人18禁在线播放| 黄网站色视频无遮挡免费观看| 国产免费av片在线观看野外av| 精品国产美女av久久久久小说| 给我免费播放毛片高清在线观看| 久久久久久久久中文| 国语自产精品视频在线第100页| 男女做爰动态图高潮gif福利片| 一区福利在线观看| 好男人电影高清在线观看| av有码第一页| 老司机午夜十八禁免费视频| 精品国产乱子伦一区二区三区| 老司机在亚洲福利影院| 他把我摸到了高潮在线观看| 国产成人av教育| 热re99久久国产66热| 欧美三级亚洲精品| 久热爱精品视频在线9| av天堂在线播放| 国产精品精品国产色婷婷| 首页视频小说图片口味搜索| 日韩精品中文字幕看吧| 少妇熟女aⅴ在线视频| 亚洲精品久久成人aⅴ小说| 亚洲aⅴ乱码一区二区在线播放 | 狠狠狠狠99中文字幕| 18禁黄网站禁片午夜丰满| 亚洲 欧美一区二区三区| 久久婷婷成人综合色麻豆| 曰老女人黄片| 国产av不卡久久| 亚洲国产精品成人综合色| 亚洲欧美激情综合另类| 亚洲av五月六月丁香网| 色综合亚洲欧美另类图片| 欧美黑人巨大hd| 人人澡人人妻人| 国产成人欧美| 国产免费av片在线观看野外av| 制服诱惑二区| 久久人妻av系列| 国产人伦9x9x在线观看| 免费在线观看影片大全网站| 亚洲一码二码三码区别大吗| 欧美成狂野欧美在线观看| 成人18禁在线播放| 午夜日韩欧美国产| 啦啦啦免费观看视频1| a在线观看视频网站| 麻豆国产av国片精品| 人人妻人人澡人人看| 欧美日韩亚洲国产一区二区在线观看| 亚洲五月色婷婷综合| 1024香蕉在线观看| 久久久久久久精品吃奶| videosex国产| 欧美国产日韩亚洲一区| 日本熟妇午夜| 久久亚洲精品不卡| 午夜精品在线福利| www.精华液| 天天躁狠狠躁夜夜躁狠狠躁| 999久久久国产精品视频| 欧美日韩乱码在线| 很黄的视频免费| 午夜精品在线福利| 99国产精品99久久久久| 国产又爽黄色视频| 国产欧美日韩一区二区精品| 欧美激情久久久久久爽电影| av中文乱码字幕在线| 久久中文字幕人妻熟女| 国产精品永久免费网站| 国产精品综合久久久久久久免费| 国产精品av久久久久免费| 男人操女人黄网站| 亚洲国产中文字幕在线视频| av超薄肉色丝袜交足视频| 亚洲自拍偷在线| 日本黄色视频三级网站网址| 久久久久久九九精品二区国产 | 亚洲国产高清在线一区二区三 | 免费在线观看完整版高清| 国产黄色小视频在线观看| 搡老妇女老女人老熟妇| 亚洲国产中文字幕在线视频| 搞女人的毛片| 亚洲国产毛片av蜜桃av| 午夜亚洲福利在线播放| 色av中文字幕| 精品国产亚洲在线| av免费在线观看网站| 国产野战对白在线观看| 久久香蕉国产精品| 久久中文字幕人妻熟女| 亚洲成av人片免费观看| 制服人妻中文乱码| 国产亚洲精品综合一区在线观看 | 搡老熟女国产l中国老女人| 夜夜看夜夜爽夜夜摸| 国产私拍福利视频在线观看| 狠狠狠狠99中文字幕| 精品一区二区三区四区五区乱码| 国内精品久久久久精免费| 亚洲午夜精品一区,二区,三区| 久久久国产欧美日韩av| 美女高潮到喷水免费观看| av在线天堂中文字幕| 免费人成视频x8x8入口观看| 国产成人欧美在线观看| 国内精品久久久久精免费| av天堂在线播放| 一进一出好大好爽视频| 最近最新中文字幕大全免费视频| 久久香蕉激情| 观看免费一级毛片| 好看av亚洲va欧美ⅴa在| 亚洲男人的天堂狠狠| 天天一区二区日本电影三级| 国产男靠女视频免费网站| 精品国产乱码久久久久久男人| 亚洲九九香蕉| 嫩草影院精品99| 精华霜和精华液先用哪个| 亚洲七黄色美女视频| 精品久久久久久久久久免费视频| 色哟哟哟哟哟哟| 亚洲中文av在线| 色综合欧美亚洲国产小说| 黄色丝袜av网址大全| 成人一区二区视频在线观看| 身体一侧抽搐| 欧美激情极品国产一区二区三区| 久久九九热精品免费| 欧美中文综合在线视频| 成年版毛片免费区| 精品国产美女av久久久久小说| 免费观看人在逋| 18美女黄网站色大片免费观看| 国产区一区二久久| 久久热在线av| 国产区一区二久久| 欧美国产精品va在线观看不卡| 亚洲精品中文字幕在线视频| 男女做爰动态图高潮gif福利片| 狠狠狠狠99中文字幕| 婷婷六月久久综合丁香| 欧美激情高清一区二区三区| 亚洲第一欧美日韩一区二区三区| 十分钟在线观看高清视频www| 看片在线看免费视频| 久久久国产欧美日韩av| 在线天堂中文资源库| 久久精品影院6| 亚洲黑人精品在线| 国产片内射在线| 欧美不卡视频在线免费观看 | 亚洲九九香蕉| 欧美一级a爱片免费观看看 | 特大巨黑吊av在线直播 | 日韩精品免费视频一区二区三区| 中文字幕人妻熟女乱码| 国产亚洲av高清不卡| av有码第一页| 最近最新中文字幕大全免费视频| 黑人操中国人逼视频| 日韩精品免费视频一区二区三区| 97超级碰碰碰精品色视频在线观看| 亚洲av五月六月丁香网| 色综合站精品国产| 欧美日韩福利视频一区二区| 国产精品美女特级片免费视频播放器 | 色播在线永久视频| 老熟妇仑乱视频hdxx| 国产在线观看jvid| 亚洲熟妇中文字幕五十中出| 国产av一区在线观看免费| 91字幕亚洲| 日韩高清综合在线| 亚洲专区字幕在线| 在线天堂中文资源库| av超薄肉色丝袜交足视频| 成人精品一区二区免费| 一区二区日韩欧美中文字幕| 老司机午夜十八禁免费视频| 久久国产亚洲av麻豆专区| 草草在线视频免费看| 99久久精品国产亚洲精品| 99国产精品99久久久久| 99热只有精品国产| 特大巨黑吊av在线直播 | 19禁男女啪啪无遮挡网站| 欧美中文日本在线观看视频| 老司机靠b影院| 免费观看人在逋| 成年女人毛片免费观看观看9| 一级黄色大片毛片| 亚洲av熟女| 久久久水蜜桃国产精品网| 麻豆成人午夜福利视频| 美女国产高潮福利片在线看| www日本黄色视频网| 亚洲精品久久国产高清桃花| 美国免费a级毛片| 亚洲欧美日韩无卡精品| e午夜精品久久久久久久| 中文在线观看免费www的网站 | 女人爽到高潮嗷嗷叫在线视频| 欧美日本亚洲视频在线播放| 一本一本综合久久| 波多野结衣巨乳人妻| 亚洲精品国产区一区二| 最近最新免费中文字幕在线| 色综合欧美亚洲国产小说| 黄片播放在线免费| 妹子高潮喷水视频| 国产一区二区激情短视频| 黄色a级毛片大全视频| 久热这里只有精品99| 最近最新中文字幕大全免费视频| 国产成人精品久久二区二区免费| 久久精品影院6| 国产精品一区二区三区四区久久 | 亚洲第一av免费看| 男人的好看免费观看在线视频 | 看黄色毛片网站| 国产一区二区三区在线臀色熟女| svipshipincom国产片| 亚洲av成人不卡在线观看播放网| 国产欧美日韩一区二区精品| 波多野结衣高清无吗| 精品欧美国产一区二区三| 大型黄色视频在线免费观看| 操出白浆在线播放| 国产精品久久久av美女十八| 国产单亲对白刺激| 亚洲激情在线av| 99久久精品国产亚洲精品| 亚洲欧美日韩无卡精品| 国产成人欧美在线观看| 香蕉av资源在线| 国内久久婷婷六月综合欲色啪| 美女高潮喷水抽搐中文字幕| 国产精品一区二区免费欧美| 露出奶头的视频| 免费一级毛片在线播放高清视频| 黄频高清免费视频| 99国产精品一区二区三区| 中亚洲国语对白在线视频| 亚洲色图av天堂| 国产色视频综合| 欧美精品亚洲一区二区| 久久中文字幕人妻熟女| 搞女人的毛片| 亚洲精品久久国产高清桃花| 黄网站色视频无遮挡免费观看| 免费在线观看黄色视频的| 欧美三级亚洲精品| 非洲黑人性xxxx精品又粗又长| 国产精品综合久久久久久久免费| 午夜激情福利司机影院| 亚洲精品一区av在线观看| 亚洲欧美精品综合久久99| 亚洲国产精品999在线| 国产av一区在线观看免费| 国产蜜桃级精品一区二区三区| 怎么达到女性高潮| 日韩三级视频一区二区三区| 亚洲国产日韩欧美精品在线观看 | 我的亚洲天堂| 亚洲精品色激情综合| 午夜日韩欧美国产| 国产一区二区三区在线臀色熟女| 国产黄片美女视频| 麻豆成人午夜福利视频| 丁香欧美五月| 校园春色视频在线观看| АⅤ资源中文在线天堂| 校园春色视频在线观看| АⅤ资源中文在线天堂| 一本大道久久a久久精品| 日本免费a在线| 一二三四在线观看免费中文在| 久久天躁狠狠躁夜夜2o2o| 丝袜在线中文字幕| 国产成人一区二区三区免费视频网站| 久久国产精品男人的天堂亚洲| 美女扒开内裤让男人捅视频| 亚洲精品色激情综合| 免费在线观看日本一区| 91av网站免费观看| 亚洲最大成人中文| 亚洲色图 男人天堂 中文字幕| 老司机在亚洲福利影院| 亚洲色图 男人天堂 中文字幕| 久久婷婷成人综合色麻豆| 性欧美人与动物交配| 免费看a级黄色片| 黄色丝袜av网址大全| 国产一区在线观看成人免费| 久久久久久久久免费视频了| 免费在线观看完整版高清| 国产亚洲精品av在线| 香蕉丝袜av| 欧美成人午夜精品| 国产av又大| 亚洲国产毛片av蜜桃av| 可以在线观看的亚洲视频| 成人国产一区最新在线观看| 免费搜索国产男女视频| 日韩国内少妇激情av| 成人免费观看视频高清| 一区二区三区国产精品乱码| 国产一卡二卡三卡精品| 国产成人欧美在线观看| 男女午夜视频在线观看| 禁无遮挡网站| 欧美成人午夜精品| 精品免费久久久久久久清纯| 看片在线看免费视频| 国产亚洲欧美在线一区二区| 性欧美人与动物交配| 男人舔女人的私密视频| 一级作爱视频免费观看| 久久国产精品影院| 免费看美女性在线毛片视频| 在线播放国产精品三级| 亚洲美女黄片视频| 一本久久中文字幕| 夜夜看夜夜爽夜夜摸| 欧美在线一区亚洲| 女人爽到高潮嗷嗷叫在线视频| 欧美日韩亚洲综合一区二区三区_| 啦啦啦韩国在线观看视频| 亚洲精品久久成人aⅴ小说| 国产亚洲欧美精品永久| 日韩欧美国产一区二区入口| 国产视频内射| 精品一区二区三区视频在线观看免费| 51午夜福利影视在线观看| 无限看片的www在线观看| or卡值多少钱| 中文资源天堂在线| 亚洲熟妇熟女久久| 国产精品久久电影中文字幕| 男女做爰动态图高潮gif福利片| 欧美中文日本在线观看视频| 国产精品久久久av美女十八| 女警被强在线播放| 又紧又爽又黄一区二区| 午夜免费激情av| 老司机深夜福利视频在线观看| av视频在线观看入口| 精品久久久久久久人妻蜜臀av| 亚洲男人天堂网一区| 中文字幕av电影在线播放| 亚洲av成人av| 国产精品野战在线观看| 亚洲人成77777在线视频| 亚洲一区中文字幕在线| 两性夫妻黄色片| 国产在线观看jvid| 91大片在线观看| 性色av乱码一区二区三区2| av免费在线观看网站| 欧美色视频一区免费| 欧美又色又爽又黄视频| 少妇的丰满在线观看| 日韩三级视频一区二区三区| 美国免费a级毛片| 制服诱惑二区| 国产高清视频在线播放一区| 日本在线视频免费播放| 一区福利在线观看| 两个人看的免费小视频| 51午夜福利影视在线观看| 欧美成人午夜精品| 久久精品国产99精品国产亚洲性色| 国产av一区二区精品久久| 好看av亚洲va欧美ⅴa在| 99久久无色码亚洲精品果冻| 精品人妻1区二区| 一区二区三区精品91| 亚洲国产精品sss在线观看| 首页视频小说图片口味搜索| 91麻豆精品激情在线观看国产| 老司机深夜福利视频在线观看| 久久精品成人免费网站| 欧美日本亚洲视频在线播放| 法律面前人人平等表现在哪些方面| 久久久久久大精品| 成人18禁高潮啪啪吃奶动态图| 亚洲精品中文字幕一二三四区| 一本大道久久a久久精品| 男人操女人黄网站| 久久亚洲精品不卡| 日日夜夜操网爽| 丝袜人妻中文字幕| 亚洲全国av大片| 两个人看的免费小视频| 日韩欧美三级三区| 天天一区二区日本电影三级| 免费观看人在逋| 麻豆成人av在线观看| 久久久久久久午夜电影|